Proprietary Technology PlatformsLadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.

Partnership OpportunitiesLadRx's strategy of forming partnerships and licensing agreements with larger pharmaceutical companies can enhance its market reach and provide necessary financial support for R&D.

No DebtThe absence of debt provides LadRx with some financial flexibility, allowing the company to focus on strategic investments and partnerships without the burden of interest obligations.

Bears Say

Negative EquityNegative equity suggests that LadRx is facing financial distress, which could hinder its ability to invest in R&D and commercialize its drug candidates effectively.

Lack Of RevenueThe absence of revenue generation highlights the challenge LadRx faces in commercializing its projects, which is critical for sustaining operations and achieving profitability.

Board Member ResignationThe resignation of a board member can signal potential governance issues or strategic disagreements, impacting investor confidence and long-term strategic direction.

LadRx News

LadRx Liquidates Assets Amid Leadership Resignations

LadRx ( ($LADX) ) just unveiled an announcement. On July 28, 2025, LadRX Corporation entered into a General...

7M ago

LADX

LadRx Seeks FDA Approval for Aldoxorubicin

LadRx ( ($LADX) ) just unveiled an announcement. On December 11, 2024, LadRx Corporation announced its intention to...

8M ago

LADX

LadRx Board Member Joel Caldwell Resigns

LadRx ( ($LADX) ) just unveiled an update. On April 14, 2025, Joel Caldwell resigned from the board...

10M ago

LADX

LadRx Strategic Shifts in Licensing and Royalty Agreements

The latest update is out from LadRx (LADX). On June 3, 2024, LadRx Corporation ended its exclusive worldwide...

2y ago

LADX

LADX FAQ

What was LadRx’s price range in the past 12 months?

LadRx lowest stock price was $0.00 and its highest was $2.40 in the past 12 months.

What is LadRx’s market cap?

LadRx’s market cap is $51.24K.

When is LadRx’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were LadRx’s earnings last quarter?

Currently, no data Available

Is LadRx overvalued?

According to Wall Street analysts LadRx’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LadRx pay dividends?

LadRx does not currently pay dividends.

What is LadRx’s EPS estimate?

LadRx’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LadRx have?

LadRx has 495,092 shares outstanding.

What happened to LadRx’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of LadRx?

Currently, no hedge funds are holding shares in LADX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.